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THE DOS AND DON’TS IN PAYER COMMUNICATION. A QUALITATIVE 
RESEARCH ACROSS FIVE EUROPEAN COUNTRIES
Guhl AK1, Gbenedio T1, Vekaria R1, Shepelev J1, Kolominsky-Rabas P2
1GfK HealthCare, London, UK; 2Centre for Health Technology Assessment (HTA) and 
Public Health (IZPH), University of Erlangen-Nurnberg, Erlangen, Germany
OBJECTIVES: National authorities across Europe implement both controls and incen-
tives to inﬂ uence the supply and demand of pharmaceuticals and medical devices. 
Today, greater emphasis is placed on increasing efﬁ ciency in the resources spent on 
health care via tighter controls on pricing and reimbursement regulations. Companies 
increasingly face the challenge to communicate their value propositions towards 
payers adequately. We investigated in 5 European countries (D,F,UK,NL,I) if compa-
nies meet payers expectations and also asked for suggestions how companies could 
improve. METHODS: A questionnaire was developed, validated and translated into 
the local language. Some questions were speciﬁ c to the national health care system. 
In total 20 face—to- face interviews were conducted with decision makers at various 
levels. All interviews were recorded. RESULTS: The expectations among payers across 
Europe with regard to industry communication vary widely. The emphasis lies in the 
presentation of scientiﬁ c data with more focus on clinical rather than economic data. 
Some of the interviewees revealed some poor examples and mistakes made by com-
panies, others gave us insights into what an “ideal” communication platform with the 
industry could look like on a national level. CONCLUSIONS: The results showed 
that even in Europe there is a huge variety how to communicate with payers from an 
industry perspective. Cultural and health care system speciﬁ cs need to be taken into 
account to develop successful payer communication strategies.
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SENSE OF COHERENCE—AS MEDIATING FACTOR IN REMAINING 
EMPLOYED IN HEALTH CARE PROFESSION
Roznár J, Oláh A, Tóth Á, Betlehem J, Boncz I, Müller Á, Jeges S
University of Pécs, Pécs, Hungary
OBJECTIVES: To prove the hypothesis that sense of coherence has a signiﬁ cant 
mediating role in keeping career in health care. METHODS: Our database: students 
in the programme of nursing (n = 203) versus randomly selected sample of students 
studying in other programmes (n = 196); and health care professionals (n = 96) vs. a 
randomly selected sample of people employed elsewhere but not in health care (n = 
741). Anonym self-completed questionnaires were used: Antonovsky’s SOC scale vali-
dated on Hungarian sample; Hennenhofer’Heil’s vegetative lability test and a health 
self-estimation scale. Used statistical methods: variance analysis and multinomial 
logistic regression. RESULTS: According to the ANOVA and post hoc tests, global 
sense of coherence of students studying in health care programmes was signiﬁ cantly 
lower (p < 0,001) than that of those students studying in other programmes; the results 
of health care professionals did not signiﬁ cantly differ from the control sample. The 
highest SOC were scored by those health care professionals who were studying besides 
working. According to the indicators of state of health the health self-estimation of 
health care students was signiﬁ cantly lower than that of those participating in other 
programmes (based on the post hoc t-tests, P < 0,05) however, between the two 
samples of employees there was no signiﬁ cant difference. We have proved with mul-
tinominal logistic regression models that SOC and the state of health are mostly 
inﬂ uenced by physical activity. CONCLUSIONS: Our hypothesis has been conﬁ rmed 
by the results. Relatively more health care students with a high SOC are employed in 
the health care. This could be the explanation for the phenomenon that health care 
students have lower SOC compared to those studying in other programmes but in 
both groups of employees there is no difference concerning SOC. This proves the 
importance of enhancement of SOC among health care students, which can be primar-
ily achieved by augmenting physical activity.
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TRAINING OF PHARMACEUTICAL SALES REPRESENTATIVES IN 
REGARD TO CHANGES IN HEALTH CARE POLICY IN GERMANY
Benkert D1, Saile C1, Schauer S1, Kossmann B1, Wasem J2, Aidelsburger P1
1CAREM GmbH, Sauerlach, Germany; 2University of Duisburg-Essen, Essen, Germany
OBJECTIVES: Due to rapid changes in health policy in Germany there is a need for 
actors in health care system for constant training about the system. Aim of the present 
study is to assess different teaching methods using the example of training pharma-
ceutical sales representatives concerning effectiveness assessment as performed by 
several institutions in Germany. METHODS: Two learning approaches are compared. 
“Health Consultant (HC)” is a training program teaching pharmaceutical sales rep-
resentatives in health policy topics using traditional training methods like talks and 
discussions. Second approach is an e-learning program. Participants were interviewed 
by questionnaires about their learning preferences. RESULTS: Evaluation of the HC 
training program shows, that the traditional teaching method is well accepted. Learn-
ing success was conﬁ rmed by subjective valuation. Most participants report a demand 
for a more ﬂ exible and individual learning approach that is compatible to their every-
day work. E-learning programmes could meet these criteria. CONCLUSIONS: Further 
studies are necessary to evaluate the learning success of both methods. Evaluation 
instruments are already developed. The dimensions that should be included are moti-
vation, workloads and structure of learning unit.
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COST-EFFECTIVENESS METHODOLOGIES OF STRATEGIES THAT AIM 
TO CHANGE THE BEHAVIOUR OF HEALTH CARE PROFESSIONALS
Kusel J, Costello S, Brooks-Rooney C, Hamer N
Costello Medical Consulting Ltd, Cambridge, UK
BACKGROUND: As the cost-effectiveness of strategies that aim to change the behav-
iour of physicians has not been widely studied, it is unclear whether a standard 
methodology is being utilised for measuring cost-effectiveness in this situation. 
OBJECTIVES: To review the current literature on the methodologies used in cost-
effectiveness evaluations of behaviour change policies for health care professionals. 
METHODS: A search of the MEDLINE database and of reference lists was performed 
up to May 2010. RESULTS: Twelve relevant evaluations, from ten publications, were 
identiﬁ ed; two discussed costs and beneﬁ ts separately and were therefore not classed 
as true cost-effectiveness evaluations. Of the remaining ten, seven were based on 
randomised controlled trials, two used a model without empirical data and one was 
a prospective cohort study. Eight of the ten evaluations utilised health outcomes as 
the main effectiveness measure, ﬁ ve of which used life-years (LY) or quality-adjusted 
LYs gained. The ten cost-effectiveness evaluations measured: implementation cost per 
LY or health outcome gained (6); total policy cost per LY gained (2); implementation 
cost per percent change in prescribing (1) and percent change in health outcome per 
pound (1). Nine took a health care provider perspective; one took a societal perspec-
tive that included patient expenditure. There was no agreement between the ten evalu-
ations as to whether physician time should be included in the cost analysis or not (yes 
(3), no (4), not stated (3)). Only two evaluations considered a time frame beyond 1 
year and took into account that future implementations would be required to maintain 
the behaviour change. Discounting of values was utilised by these evaluations (3% 
per year), and by 1 other study (percent not stated). CONCLUSIONS: More robust 
evaluations are required, with health outcomes assessed as LYs for comparison pur-
poses. Future evaluations must consider timeframe, discounting, societal costs and 
costs due to physician time.
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FIRST-IN-THERAPY PRODUCTS AND REQUIREMENTS FOR 
SUCCESSFUL HTA ASSESSMENT
Xia AD, Oraro T
Heron Evidence Development Ltd., London, UK
OBJECTIVES: To determine the necessary requirements of a ﬁ rst-in-therapy product 
to support positive HTA review. METHODS: An initial broad search was conducted 
to identify ﬁ rst-in-therapy products launching in recent years into disease areas with 
no alternative treatments. The products identiﬁ ed were eculizumab for paroxysmal 
nocturnal hemoglobinuria (PNH), pregabalin for ﬁ bromyalgia, vigabatrin for infantile 
spasms, tetrabenazine for tardive dyskinesia (TD) and chorea of Huntington’s disease, 
pirfenidone for idiopathic pulmonary ﬁ brosis (IPF), and amifampridine for Lambert-
Eaton myasthenic syndrome (LEMS). These products were then examined within 
NICE, SMC, NCPE, PBAC and CADTH websites, and information collated on clinical 
endpoints, HTA comparators and assessment outcomes to provide an understanding 
of the requirements of ﬁ rst-in-therapy products for positive review. RESULTS: Of the 
drugs selected, 4 were assessed by HTA bodies. Due to a lack of alternative therapies, 
all but one product assessed carried out trials against placebo. Clinical endpoints were 
based either on metrics agreed upon by KOLs, quality of life measures, or both. Out 
of the seven drugs studied, only vigabatrin received positive recommendation due to 
strong trial data and inclusion of an active symptomatic comparator. a number of 
ﬁ rst-in-therapy products were actually rejected by HTAs in select countries. Pregabalin 
was rejected due to unconvincing trial data despite a favourable cost per QALY and 
eculizumab was rejected due to too high an incremental cost per QALY. CONCLU-
SIONS: We can conclude that based on the products assessed, ﬁ rst-in-therapy products 
do not typically receive special consideration when assessed by HTA bodies. An active 
comparator, use of recognized endpoints and the quality of data remain as important 
requirements for positive review. Furthermore, demonstrated cost-effectiveness is 
required even in a novel disease area, thus, it will be necessary to evaluate this earlier 
in development. More focused studies need to be carried out to ascertain this trend 
on a country-by-country basis. 
HEALTH CARE USE & POLICY STUDIES – Health Technology Assessment 
Programs
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EVALUATION OF ACCEPTANCE AND REJECTION RATES OF ORPHAN 
DRUGS ACROSS SIX HTA AGENCIES
Jäkel A1, Alnwick K2
1Heron Evidence Development Ltd, Stopsley, UK; 2Heron Evidence Development Ltd, 
London, UK
OBJECTIVES: Many orphan drugs receive market authorization, however an assess-
ment of cost-effectiveness is usually required before these drugs can be reimbursed. 
Recent research has explored the differences between HTA bodies in their rates of 
acceptance/rejection of orphan drugs. The objective of this study was to consider the 
relative weight of economic and clinical reasons for rejecting orphan drug submissions 
to HTA agencies. METHODS: Six HTA websites (NICE, SMC, NCPE, CEDAC, 
PBAC, AWMSG) were searched for summary guidance on 71 licensed orphan drugs 
identiﬁ ed from a search of the Orphanet website. RESULTS: Of 53 total non-approved 
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submissions, in 53% of cases a high ICER was reported in the summary of guidance 
as a reason for rejection. In about 30% of these cases, the high drug cost was speciﬁ ed 
as the driver of the high ICER. The lack of a robust economic case was mentioned in 
45% of rejections. Limited evidence of clinical beneﬁ t was shown in 43% of cases. 
Other reasons included inadequate type or quality of clinical data (21%) and non-
acceptance of clinical positioning (11%). In 45% of cases the rejections were largely 
due to economic reasons; 6% of cases were not accepted due primarily to clinical 
reasons and in 49% of rejections the criticisms related to both the economic and 
clinical evidence. Uncertainty in the evidence was reported as a problem in most nega-
tive recommendations. CONCLUSIONS: Only slightly over half of the orphan drug 
HTA submissions to these agencies are explicitly rejected primarily on the basis of a 
high ICER. Most HTA rejections are due to a combined lack of robust economic and 
clinical evidence. This suggests that collecting the right kind of data and presenting a 
solid case that accounts adequately for any uncertainty is at least as important as 
meeting trial endpoints and choosing an optimal price.
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EVALUATION OF ACCEPTANCE AND REJECTION RATES OF ORPHAN 
DRUGS ACROSS SIX HTA BODIES
Oraro T, Alnwick K
Heron Evidence Development Ltd., London, UK
OBJECTIVES: Orphan drugs (ODs) face numerous difﬁ culties in demonstrating their 
value through rigorous HTA processes. HTA bodies may therefore choose to take into 
consideration the special circumstances of treatments for orphan indications, either 
formally or informally. The objective of this study was to examine the decisions made 
on ODs by six English-speaking HTA bodies, and assess potential trends between 
agencies. METHODS: AWMSG, CEDAC, NCPE, NICE, PBAC and SMC HTA web-
sites were searched for completed OD assessments (identiﬁ ed via Orphanet website) 
as of April 2010, and data extracted on the recommendations. Recommendations with 
restrictions were categorised as approvals. Comparisons were made to published 
approval rates for drug submissions as a whole. RESULTS: Of the 71 ODs selected, 
55 were assessed by at least one HTA body. The proportion of positive recommenda-
tions for orphan treatments was lower than published approval rates for general 
(orphan and non-orphan) HTA drug submissions in most bodies. NICE approved 
67% completed OD submissions, versus approximately 87% of drugs overall. 
However, PBAC recommended 60% of ODs compared to 54% of drugs as a whole. 
Decisions also varied substantially between agencies. CEDAC had the highest propor-
tion of rejections (73%), compared to NICE, which rejected 33%. There was also 
variation in decisions made on speciﬁ c treatments. Sutent, for example, with an orphan 
designation for renal cell carcinoma, was accepted by AWMSG, CEDAC and SMC, 
while it received a negative recommendation from NCPE, NICE and PBAC. CON-
CLUSIONS: The willingness to assess ODs varies widely by agency and drug, as do 
resultant approval rates. HTA agencies are far more likely to reject OD submissions 
than non-orphan drugs as a whole. However given the differences in their remit to 
assess ODs, direct comparisons should be interpreted with caution. Further research 
is needed to explore the reasons behind these differences in HTA agency decisions.
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A SURVEY OF HTA RESEARCH METHODS AND TRENDS IN EUROPE
ISPOR HTA SIG Research Methods/Principles Working Group
ISPOR, Lawrenceville, NJ, USA
OBJECTIVES: To describe research methods and key issues in the HTA process in 
Europe. METHODS: Representatives from HTA bodies globally were recruited by 
members of the ISPOR HTA SIG Research Methods/Principles Working Group to 
complete a 45-minute on-line survey consisting of 48 items within 4 topics related to 
1) organizational information and process; 2) primary HTA methodologies and impor-
tance of attributes; 3) HTA application and dissemination; and 4) quality of HTA 
including key issues. Data were reported for Europe. RESULTS: The survey was 
completed by 11 European countries including Austria, Denmark, France, Germany, 
Hungary, Italy, The Netherlands, Portugal, Spain, Sweden, and Switzerland. Top 
reasons technologies were evaluated included perceived impact on patient outcomes, 
potential cost, and prevalence of the condition. The most common methodologies used 
were cost/economic analyses, systematic reviews & meta-analyses, clinical trials, mod-
eling, and comparative analyses. The most important attributes (in order) were effec-
tiveness, efﬁ cacy, safety, cost-effectiveness, and budget impact. While quality of life 
was frequently assessed by >74% of European respondents, it was not listed as an 
attribute of top importance. Only 24% repeat/update the assessment at regular inter-
vals. For 82% a different organization makes the ﬁ nal decision on coverage, only 
partially relying on the report. The most common educational background for decision 
makers was physician-specialist. Stakeholders are allowed to review the report and 
are involved in assessments >50% of the time, and in the ﬁ nal decisions ~35% of the 
time. Key issues/trends included early assessment of technologies with mechanism for 
conditional coverage, increasing regional interest in HTA, reassessment/horizon scan-
ning, and link between theory and practice in HTA. CONCLUSIONS: This survey of 
representatives within HTA and reimbursement bodies provides current insight into 
the state of HTA research methods in Europe. Future research could expand the results 
to speciﬁ cally address Eastern European countries, Asia, and other emerging markets.
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NICE GUIDANCE: AN ANALYSIS OF LEVELS OF RESTRICTION BY 
DISEASE AREA
Mesa OA1, Venus A2, Lebmeier M1, Davis M1, Jones C1
1Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, Middlesex, UK; 2Bristol-Myers Squibb 
Pharmaceuticals Ltd, Princeton, NJ, USA
OBJECTIVES: To assess the outcomes of NICE’s guidance in totality and different 
disease areas. METHODS: A list of NICE Guidance published between 2007 to the 
end of 2009 was identiﬁ ed using HTAinSite™. We classiﬁ ed these recommendations 
into; ‘recommended’, ‘restricted’ and ‘not recommended’, and calculated the percent-
ages. We then analyzed these recommendations according to disease areas; ‘cardio-
vascular/metabolics’, ‘mental health’, ‘infectious diseases’, muscoskeletal conditions’, 
‘oncology’, and ‘others’. RESULTS: In 2007, NICE assessed 25 drugs, 31 in 2008 and 
18 in 2009. Of these, in 2007 NICE recommended 8 drugs (31%) for all eligible 
patients, restricted 13 (53%), and did not recommend 4 (16%). In 2008, 3 (10%) 
were recommended, 21 (68%) were restricted, and 7 (22%) were not recommended. 
Finally, in 2009, 2 (11%) treatments were recommended, while 11 (61%) received 
restricted recommendations and 5 (28%) were not recommended. Between 2007 and 
2009 NICE completed 7 appraisals in ‘cardiovascular/metabolics’ of which 4 received 
a full recommendation, while in ‘mental health’ 2 out of 2 were fully recommended. 
In contrast, in ‘infectious diseases’, 1 out of 5 was fully recommended. In ‘muscoskel-
etal conditions’ only 1 out of 21 were recommended (17 restricted and 3 not recom-
mended) while in ‘oncology’ only 1 out of 23 received a full recommendation (13 
restricted, 9 not recommended). In the ‘others’ group, 4 out of 12 received a recom-
mendation (6 restricted, 2 not recommended). If manufacturers had not proposed 
Patient Access Schemes (PAS) the proportion of guidance not recommended in 2009 
would be 44%. CONCLUSIONS: Appraisal outcomes have become more restrictive 
over time. Furthermore, low cost primary care therapeutics are more likely to receive 
a positive NICE recommendation than high cost speciality care interventions. 
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DESIGNING EUROPEAN GUIDELINES FOR HEALTH OUTCOMES AND 
COST-EFFECTIVENESS ASSESSMENTS: THE ECHOUTCOME EUROPEAN 
COMMISSION PROJECT
Beresniak A1, Auray J2, Duru G3, Medina-Lara A4, Praet J5, Sambuc R6, Tarricone R4, 
Torbica A4, De Wever A5, Lamure M7
1Data Mining International, Geneva, Switzerland; 2Cyklad Group, Rilleux la Pape, France; 
3Cyklad Group, rilleux la Pape, France; 4Bocconi University, Milano, Italy; 5Université Libre de 
Bruxelles, Brussels, Belgium; 6Université de la Mediterrannee, Marseille, France; 7University 
Claude Bernard Lyon 1, Paris, France
OBJECTIVES: Over the last decade the National Institute of Clinical Excellence in 
the UK has published guidelines for health technology assessments (HTA) that includes 
recommendations on health outcomes and cost-effectiveness assessments. In Europe, 
this has opened the opportunity for countries to either propose their own guidelines 
or use the British ones. The ECHOUTCOME project is an interdisciplinary European 
research platform funded by the seventh Framework Program of the European Com-
mission with the aim of designing new European guidelines in Health Outcomes and 
Cost-Effectiveness assessments. METHODS: This three years project is structured in 
three phases. Phase 1 aims to conduct a pan-European survey of HTA organizations 
and health outcomes use in the 27 European countries. Multiple correspondence and 
cluster analyses will be carried out to study the potential similarities and divergences 
across Europe. The objective of Phase 2 is to test the robustness and underlying 
assumptions such as reproducibility, neutrality to risk, constancy of time-trade-off 
rate, utility independence, etc. on QALYs, DALYs and HYEs measures. This testing 
will be conducted in the general population (n = 300 per country) in Belgium, France, 
Italy and UK. Phase 3 aims to propose new approaches in Health Outcomes and 
Cost-Effectiveness analyses. RESULTS: The main deliverable of the ECHOUTCOME 
project will be new European Guidelines for assessing Health Outcomes and conduct-
ing Cost-Effectiveness assessments. Of particular interest will be the recommendations 
on the practical usefulness of QALYs, DALYs and HYEs based on the experimental 
validation of their underlying assumptions. CONCLUSIONS: The ECHOUTCOME 
project is the ﬁ rst European validation study of health outcomes measures. This work 
will produce guidelines for public health decision-making in the 27 European 
countries. The ECHOUTCOME outcomes will enhance the debate and increase the 
understanding that will improve the knowledge of existing Health Outcomes 
and Cost-Effectiveness techniques and will promote new approaches for 
decision-making.
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HOW CAN THE USE OF PREDICTIVE BIOMARKERS LEAD TO POSITIVE 
HTA RECOMMENDATIONS?
Trevor NC1, Alnwick K2
1Heron Evidence Development Ltd, London, UK; 2Heron Evidence Development Ltd, Luton, 
UK
OBJECTIVES: The popularity and availability of biomarkers has rapidly increased in 
recent years, thanks to innovative advances in pharmacogenomics. Predictive biomarkers 
have high potential value in HTA as they may increase the observed efﬁ cacy and cost-
effectiveness of treatments. This study reviews, in selected major markets worldwide, 
the impact of currently available predictive biomarkers on HTA in the context of the 
agency’s evidence requirements. METHODS: A broad review of biomarker tests used 
in HTA submissions in Europe, Australia, Canada, and the US was conducted; the 
